Details for New Drug Application (NDA): 217968
✉ Email this page to a colleague
NDA 217968 describes LAPATINIB DITOSYLATE, which is a drug marketed by Natco Pharma Ltd and Teva Pharms Usa Inc and is included in two NDAs. It is available from one supplier. Additional details are available on the LAPATINIB DITOSYLATE profile page.
The generic ingredient in LAPATINIB DITOSYLATE is lapatinib ditosylate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
The generic ingredient in LAPATINIB DITOSYLATE is lapatinib ditosylate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
Summary for 217968
| Tradename: | LAPATINIB DITOSYLATE |
| Applicant: | Teva Pharms Usa Inc |
| Ingredient: | lapatinib ditosylate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Aug 16, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
